Literature DB >> 8542839

Pharmacodynamics and pharmacokinetics of carprofen in the horse.

P Lees1, Q McKellar, S A May, B Ludwig.   

Abstract

The pharmacokinetics and pharmacodynamics of the nonsteroidal anti-inflammatory drug (NSAID) carprofen have been evaluated in 6 horses using a model of acute non-immune inflammation. Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve). Mean exudate:plasma concentration ratios exceeded 1.0 at all sampling times between 2 and 48 h. Swelling at the site of acute inflammation was significantly reduced but exudate leucocyte numbers were unchanged. Although carprofen produced moderate suppression of serum thromboxane B2 and exudate prostaglandin E2 synthesis, these effects were not related to carprofen concentrations in plasma or exudate. It was concluded that the anti-oedematous action of carprofen was not attributable to inhibition of cyclo-oxygenase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8542839     DOI: 10.1111/j.2042-3306.1994.tb04370.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  3 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

2.  Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep.

Authors:  Z Cheng; A M Nolan; Q A McKellar
Journal:  Inflammation       Date:  1998-08       Impact factor: 4.092

3.  The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure.

Authors:  Tamsyn Fourie; Duncan Cromarty; Neil Duncan; Kerri Wolter; Vinny Naidoo
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.